Home Newsfeeds JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $34

JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $34

JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target from $37 to $34.

byBenzinga Newsdesk

November 17, 2022

1 minute read

JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target from $37 to $34.

Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate

By Vandana Singh

November 30, 2:03 PM

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

BIIB

Snowflake’s Solid Q3 Driven By Strongest Consumption Activity In 2 Years: 9 Of 10 Analysts Raise Their Price Targets

By Priya Nigam

November 30, 1:37 PM

Snowflake Inc (NYSE: SNOW) shares were climbing in early trading on Thursday after the company reported upbeat third-quarter results.

SNOW

Higher Stock Prices, Valuations Make Sense Because There’s Not Enough Public Equity To Go Around, Josh Brown Says: ‘It’s Not Going To Change’

By Adam Eckert

April 11, 4:12 PM

Josh Brown argues that there are several tailwinds pushing the stock market higher including AI and the prospect of rate cuts from the Federal Reserve, but there's also something else going on, and it's not going away.

SPY

Artelo Biosciences Presents New Preclinical Data On ART12.11 At The 4th Annual Med-Cannabis 2023 Conference In Germany

By Benzinga Newsdesk

December 5, 9:36 AM

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $34

Related Posts

Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate

Snowflake’s Solid Q3 Driven By Strongest Consumption Activity In 2 Years: 9 Of 10 Analysts Raise Their Price Targets

Higher Stock Prices, Valuations Make Sense Because There’s Not Enough Public Equity To Go Around, Josh Brown Says: ‘It’s Not Going To Change’

Artelo Biosciences Presents New Preclinical Data On ART12.11 At The 4th Annual Med-Cannabis 2023 Conference In Germany